Quarterly ResultMay 13, 2026, 04:08 PM
Dyadic Q1 Revenue +182.3% to $1.11M; Commercial Milestones Achieved
AI Summary
Dyadic International reported a significant increase in Q1 2026 total revenue, up 182.3% to $1.11 million, driven by growth in research and development, grant, and license revenue. The company also announced several key commercial milestones, including the launch of AlbuFree DX, an expanded collaboration with Fermbox Bio, and new distribution and development agreements. Despite these advancements, Dyadic recorded a net loss of $1.95 million for the quarter, with cash reserves at $6.6 million.
Key Highlights
- Dyadic Q1 2026 total revenue increased 182.3% to $1,110,956.
- Net loss for Q1 2026 was $1,954,683, or $(0.05) per share, down from $(0.07) per share YoY.
- Cash, cash equivalents, restricted cash, and investment grade securities were $6.6 million as of March 31, 2026.
- Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals.
- Expanded strategic collaboration with Fermbox Bio, launching recombinant DNase I.
- Signed an OEM distribution agreement with IBT Bioservices for global commercialization.
- Entered a development and commercialization agreement with BRIG Bio for animal-free bovine alpha-lactalbumin.